AKT1 and ovarian carcinoma: Thioridazine inhibits cell viability and induces cell death through inhibition of the PI3K/Akt signaling pathway in ovarian cancer and in cervical and endometrial cancer cells.11, 12 In addition, thioridazine inhibits angiogenesis and tumor growth in ovarian cancer xenografts by inhibiting PI3K/Akt signaling.17 In our study, thioridazine also inhibited Akt phosphorylation (Supplementary Figure S1a).